1. Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics

   • Daniel Savitt
   • Joseph Jankovic

   Leading Article 13 April 2019 Pages: 797 - 810

2. Drugs in Development for Acute Kidney Injury

   • Matthew Hulse
   • Mitchell H. Rosner

   Leading Article 19 April 2019 Pages: 811 - 821

   

3. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer

   • Sally C. M. Lau
   • Ullas Batra
   • Herbert H. Loong

   Review Article 08 May 2019 Pages: 823 - 831

4. Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents

   • Lydia L. Benitez
   • Peggy L. Carver

   Review Article 15 May 2019 Pages: 833 - 853

   

5. Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?

   • Aurelie Lenglet
   • Nicolas Fabresse
   • Ziad A. Massy

   Original Research Article 06 May 2019 Pages: 855 - 862

   

6. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy

   • Yvette N. Lamb
   • Emma D. Deeks

   Adis Drug Evaluation 16 May 2019 Pages: 863 - 874

   

7. Teriflunomide: A Review in Relapsing–Remitting Multiple Sclerosis

   • Lesley J. Scott

   Adis Drug Evaluation 16 May 2019 Pages: 875 - 886

8. Peficitinib: First Global Approval

   • Anthony Markham
   • Susan J. Keam

   AdisInsight Report 15 May 2019 Pages: 887 - 891

   

9. Risankizumab: First Global Approval

   • Kate McKeage
   • Sean Duggan

   AdisInsight Report 17 May 2019 Pages: 893 - 900

   

10. Correction to: Pegaspargase: A Review in Acute Lymphoblastic Leukaemia

    • Young-A. Heo
    • Yahiya Y. Syed
    • Susan J. Keam

    Correction Open access 17 May 2019 Pages: 901 - 901